Effectiveness and Safety of Autologous Serum Therapy in Chronic Spontaneous Urticaria in Children a Prospective Research

Abstract

Background: Chronic spontaneous urticaria (CSU) affects a large percentage of children and can have a serious negative impact on their quality of life. Autologous serum therapy (AST) has become a promising treatment for CSU, although more research is needed to determine how safe and beneficial it is for paediatric patients.

The purpose of this prospective study was to assess the efficacy and security of AST in CSU-affected children.

Methods: The study included 100 kids who had been diagnosed with CSU in total. The Urticaria Activity Score (UAS), the primary outcome measure, and the Quality of Life (QoL) score, the secondary end measure, were evaluated at baseline and following the administration of AST for a total of 12 weeks. Adverse AST-related occurrences were also kept an eye on.

Results: The UAS scores significantly decreased after AST (p< 0.001), indicating better illness management. The QoL scores also showed a substantial improvement (p<0.001), which was indicative of greater wellbeing. The few adverse effects that did occur were mostly local erythema and moderate discomfort at the injection site.

Conclusion: The results of this study show that AST is both beneficial and safe in lowering disease activity and enhancing quality of life in children with CSU. The prospective treatment alternative provided by AST has a good safety profile, making it an important factor to take into account while managing CSU in paediatric patients.